Investor Presentaiton

Existing portfolio 1 Strong business momentum Diversified portfolio growth Efficient compounding engine Sustainable long-term growth Growth diversified across multiple components of the portfolio Portfolio components 2 3 4 Future royalty acquisitions Development- stage pipeline Recently launched products (2) Established growth portfolio (3) ~$10-12bn 5-year opportunity High-single to low-double digit % returns on approved and teens % on development-stage 10 potential pipeline therapy candidates gantenerumab excluded from outlook 9 newly-launched growth therapies with significant long-term runway ~25 commercial therapies including 12 that were blockbusters in 2021 ROYALTY PHARMA 2. Recently launched products includes products approved in 2018 or later. 3. Established growth portfolio includes products approved before 2018. Adjusted Cash Receipts (1) ("top-line") Cumulative CAGR (excl. gantenerumab)(1): $3.0-3.5bn 11-14% 4 3 ~8% 2 ~7% 1 ~3% $1.8bn 2020 2025e 1. See slide 114 for definitions and factors that may impact the achievement of our growth outlook. Growth outlook includes future royalty acquisitions and excludes development-stage pipeline candidate gantenerumab for Alzheimer's disease. Refer to the Appendix for a GAAP to non-GAAP reconciliation. 89

View entire presentation